DAVIS, Calif., March 10, 2014 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (MBI) (Nasdaq:MBII), a leading global provider of bio-based pest management and plant health products announced it has received a United States patent covering applications of products containing anthraquinone derivatives, such as the company's flagship product Regalia® Biofungicide. The issued claims cover methods for increasing plant growth, root initiation and extension when plant roots are treated with an anthraquinone derivative. The new patent protects uses of Regalia and any future MBI products containing these active ingredients.
Data has shown Regalia applied to bare-root plants increases transplant health, and root mass and weight. Fruit weight, new root counts and plant viability have also been increased by pre-plant dip, soil drench and drip irrigation applications of Regalia. "Growers have seen firsthand for a number of years how Regalia and its anthraquinone-based active ingredient improves plant health, vigor and yield. Now, with this patent MBI is able to pursue new products and improvements using these natural product compounds to benefit growers even more," said Pam Marrone, CEO of Marrone Bio Innovations.
She adds, "This patent is a result of MBI's unparalleled capability to in-license technology, utilize our proprietary screening platform to identify new potential uses and, ultimately, create and protect unique intellectual property through new patents."
About Marrone Bio Innovations
Marrone Bio Innovations, Inc. (Nasdaq:MBII) is a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental, and water treatment markets. Our effective and environmentally responsible solutions help customers operate more sustainably while controlling pests, improving plant health, and increasing crop yields. We have a proprietary discovery process, a rapid development platform, and a robust pipeline of pest management and plant health product candidates. At Marrone Bio Innovations we are dedicated to pioneering better biopesticides that support a better tomorrow for users around the globe. For more information, please visit www.marronebio.com.
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements relating the results from field trials. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements, including the difficulty in predicting the outcome of product research and development efforts and regulatory approvals. Additional relevant information concerning risks can be found in the Form 10-Q that the Company filed with the Securities and Exchange Commission on November 8, 2013.